Gout flares, serum urate and seasonality: a descriptive cohort study
-
By
-
Samuel Finnikin
-
Christian D. Mallen
-
Edward Roddy
-
January 6, 2026
Clinical Scorecard: Seasonal Variations in Gout Attacks and Serum Urate Levels: A Cohort Analysis
At a Glance
| Category | Detail |
|---|
| Condition | Gout, an inflammatory arthritis caused by monosodium urate crystal deposition |
| Key Mechanisms | MSU crystal formation influenced by serum urate levels, temperature, pH, and physical shock |
| Target Population | Adults aged 20 years and over with incident gout in the UK |
| Care Setting | Primary care, with management primarily outside specialist settings |
Key Highlights
- Gout flares show seasonal variation, peaking in spring (USA, Korea, Italy) or summer (UK).
- Serum urate levels correlate with gout flare risk but may be temporarily reduced during flares.
- Serum urate testing is suboptimal; around 40% of gout patients lack SU measurements.
Guideline-Based Recommendations
Diagnosis
- Measure serum urate to aid gout diagnosis, ideally at least 14 days after a flare to avoid transiently low SU levels.
- Use clinical coding combined with SU levels and prescribing data for accurate gout diagnosis.
Management
- Use urate-lowering therapies (allopurinol, febuxostat) to reduce serum urate and flare risk.
- Avoid initiating ULT during acute flares; exclude patients on ULT when studying natural flare patterns.
Monitoring & Follow-up
- Monitor serum urate levels when initiating or managing ULT.
- Recognize that SU levels may fluctuate seasonally and with flares.
Risks
- Higher serum urate levels increase risk of gout flares.
- Lower temperatures and dehydration may promote MSU crystallization and flares.
Patient & Prescribing Data
UK adults with incident gout not on urate-lowering therapy
ULT initiation censors flare observation; colchicine or NSAIDs prescribed for flares but may be used prophylactically with ULT initiation.
Clinical Best Practices
- Exclude patients on ULT when studying natural gout flare patterns to avoid confounding.
- Allow a 30-day grace period post-flare to distinguish separate flare events.
- Use multiple data sources (prescriptions, healthcare visits, coded diagnoses) to identify gout flares.
- Consider demographic covariates (age, sex, ethnicity) in gout flare risk assessment.
- Exclude biologically implausible serum urate values and zero entries from analysis.
References
